PHARMACOLOGICAL EVALUATION OF 7-HYDROXY-4-METHYL COUMARIN EMULGEL IN IMIQUIMOD-INDUCED PSORIATIC MICE MODEL

Abstract

Psoriasis is a condition of chronic inflammatory type with the inappropriate regulation of the immune system. Psoriasis is a complex system comprising an immune part of inflammation in which pro-inflammatory cytokines and immune cells take part. It is known that coumarins possess anti-inflammatory parameters, which is due to the regulation of the most significant inflammatory pathways. The coumarins hold the capability to minimize proinflammatory cytokine IL-6, IL-23, L 17-A, TNF alpha, IL-1, IFn-gamma, and oxidative stress. The current work tries to assess the anti-inflammatory and antioxidant activity of a new emulgel comprising a coumarin compound 7-hydroxy-4-methyl coumarin in a psoriasis mouse model. The acute toxicity of the 7-Hydroxy- 4- methyl coumarin derivative was done in response to OECD 423 and 402. The treatment of pacific mice with imiquimod induced psoriatic lesions on bare mice back. The standard drugs included calcipotriene and acitretin. The selection of different doses of 7-hydroxy-4-methyl coumarin derivative was done based on conducting toxicity studies. To establish the efficiency of emulgel and conventional therapy, the histopathology of skin tissues was accomplished. The effect of 7-H-4-MC was evaluated in inflammatory markers and oxidative stress in psoriatic mice models. Findings were an improvement in the level of pro- inflammatory cytokines and oxidative stress with large dose of 7-H-4-MC, whereby, results were found to reduce psoriatic lesions. Therefore, 7-H-4-MC could continue to be tested clinically, or we can say that 7-H-4-MC is effective when it comes to psoriasis.